What is the estimated potential liability or settlement amount for Spectrum Pharmaceuticals from this class action lawsuit?

Answer: The press release does not disclose a dollar figure for the potential liability or settlement that Spectrum Pharmaceuticals (SPPI) could face in the securities‑class‑action case. Pomerantz LLP’s notice only confirms that the lead‑plaintiff appointment process is being reopened and that investors must act by the upcoming deadline; no estimate of exposure—whether a few million dollars or a double‑digit‑million‑range settlement—was provided in the material we have.

Trading implications:

- Fundamental risk: Without a disclosed exposure, the lawsuit remains a “black‑box” tail‑risk factor. Until the case proceeds to a settlement or judgment, the market will price in a modest, but uncertain, downside potential.

- Technical view: SPPI has been trading in a tight range around the $1.00‑$1.20 level, with the 50‑day moving average near $1.08 and the 200‑day average around $1.05. A breach below the $1.00 support could signal the market’s reaction to any negative settlement news, while a bounce above $1.20 would suggest the market is discounting the lawsuit’s impact.

- Actionable stance: Given the lack of a concrete liability estimate, maintain a neutral‑to‑defensive position. Consider capping downside with a stop just below the $1.00 support if you are long, or look for a short‑entry if the stock breaks that level on high volume, while staying mindful that the true exposure may still be unknown until further disclosures.